Methodist Healthcare Acquires IR-MED’s PressureSafe Device for Usability Study: Decision Support Tool Aims to Reduce Significant Burden of Pressure Injuries in Healthcare Page 1

• Patient enrollment and monitoring with PressureSafe has begun
• In a similar study conducted among the world’s 2^nd largest HMO, PressureSafe had a 92% effectiveness in detection and the incidence of pressure ulcers was reduced by 50% during the study
• A skin color agnostic decision support device, PressureSafeuses an AI-based algorithm and infrared light to feel beneath the skin surface and detect pressure ulcer biomarkers
• $26.8 billion is spent annually on the prevention and treatment of pressure sores,
  and pressure sores result directly in death of 60,000 people per year in the US

Rosh Pina, Israel, September 10, 2024 (GLOBE NEWSWIRE) — IR-MED Inc.(“IR-MED” or the “Company”) (OTCQB:IRME), developer of a non-invasive, artificial intelligence (AI)-based spectrographic analysis technology platform to address critical healthcare needs, today announced the initiation of a usability study for its lead product, PressureSafe, in San Antonio, Texas. Methodist health careThe study, titled “Safety and Effectiveness of the PressureSafe Device for Early Detection of Pressure Injuries in People with Diverse Skin Tones, Including Dark Skin Tones,” has received approval from Methodist Healthcare and has begun enrollment and patient monitoring. Methodist Healthcare is widely regarded as one of the most respected healthcare providers in the region. With a growing network of care locations, including hospitals, surgery centers, emergency departments and family health clinics, Methodist Healthcare serves 608,000 patients each year, including 11,000 deliveries and 330,000 ED visits.

PressureSafe, an innovative non-invasive medical device using infrared optical spectroscopy and an AI-based algorithm, is designed to effectively detect early pressure injuries for all skin tones. PressureSafe is skin tone agnostic as it uses infrared light to detect biomarker changes beneath the skin’s surface. The decision support device is FDA-cleared.

Study Principal Investigator and Director of Professional Nursing Practice at Methodist Healthcare, Mary Lee Potter, PhD, MBA, RN, CWOCN, noted, “This is a very important study for our nurses and the entire medical team as we continually strive to improve outcomes for our patients. We look forward to using PressureSafe at Methodist Hospital Metropolitan and are eager to evaluate its potential to increase the accuracy of early detection and prevention of pressure injuries. Because the device evaluates tissues beneath the skin and digitally assesses biomarkers, the technology has the potential to objectively improve upon human visual inspection, which is very exciting to us.”